BioMarin寻求剥离血友病A基因疗法罗克塔维安

2025-10-28 05:13

BioMarin Pharmaceutical (NASDAQ:BMRN) said it will look to divest Roctavian (valoctocogene roxaparvovec), a one-time gene therapy for hemophilia A to focus more on its core treatments.
Offloading Roctavian means the biotech will have seven marketed therapies. It most profitable treatment is Voxzogo (vosoritide) to treat achondroplasia, a rare form of dwarfism. In Q3, its accounted for $218M of $776M in total revenue. By comparison, Roctavian earned just $3M, down from $7M in the year-ago period.
Part of the issue with Roctavian is its price tag. In 2023, when the drug was approved, BioMarin set the list price at $2.9M.
BioMarin released its Q3 financial results after Monday's closing bell. It missed on both lines.
In addition, the company cut its 2025 non-GAAP diluted EPS guidance to $3.50-$3.60 from $4.40-$4.55 made in August. Consensus is $3.84.

More on BioMarin Pharmaceutical